Abstract |
The importance of the tumor microenvironment in cancer progression has been well studied for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in enhancing the immune responses in patients with cancer, particularly colorectal cancer (CRC). Notably, CRCs are extraordinarily heterogeneous and mostly are microsatellite-stable (MSS) or cold tumors, which means that the immune response is not usually as strong as that of foreign cells. T-cell immunoglobulin and ITIM domain (TIGIT) is a new immune checkpoint receptor overexpressed inside the CRC tumor-immune microenvironments. Moreover, several studies have shown that TIGIT in combination with other ICIs and/or conventional treatments, can lead to a robust anti- tumor response in CRC. This review looks deep inside TIGIT expression patterns, their various functions, and possible immunotherapy strategies to increase survival rates and decrease immune-related adverse events.
|
Authors | Mehrdad Fathi, Inna Pustokhina, Sergey V Kuznetsov, Mars Khayrullin, Mohammad Hojjat-Farsangi, Vahid Karpisheh, Ali Jalili, Farhad Jadidi-Niaragh |
Journal | IUBMB life
(IUBMB Life)
Vol. 73
Issue 5
Pg. 726-738
(05 2021)
ISSN: 1521-6551 [Electronic] England |
PMID | 33686787
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2021 International Union of Biochemistry and Molecular Biology. |
Chemical References |
- Antigens, CD
- CD96 antigen
- Immune Checkpoint Inhibitors
- Immune Checkpoint Proteins
- Receptors, Immunologic
- T cell Ig and ITIM domain protein, mouse
- TIGIT protein, human
|
Topics |
- Adenocarcinoma
(immunology, pathology, therapy)
- Amino Acid Motifs
- Animals
- Antigens, CD
(immunology)
- CRISPR-Cas Systems
- Colorectal Neoplasms
(immunology, pathology, radiotherapy, therapy)
- Combined Modality Therapy
- Gastrointestinal Microbiome
- Gene Expression Regulation, Neoplastic
- Humans
- Immune Checkpoint Inhibitors
- Immune Checkpoint Proteins
(immunology)
- Immunotherapy
(methods)
- Mice
- Prognosis
- Protein Domains
- Receptors, Immunologic
(antagonists & inhibitors, biosynthesis, deficiency, genetics, immunology)
- Tumor Microenvironment
|